We are live on ! Find out more
AG

Algert Global Portfolio holdings

AUM $6.65B
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+10.43%
1 Year Est. Return
+53.68%
3 Year Est. Return
+140.8%
5 Year Est. Return
+204.57%
10 Year Est. Return
+1,528.09%
AUM
$2.55B
AUM Growth
+$71.7M
Cap. Flow
-$81.9M
Cap. Flow %
-3.21%
Top 10 Hldgs %
5.31%
Holding
1,322
New
211
Increased
334
Reduced
433
Closed
270

Top Buys

Rank Stock Value
1
MATX icon
Matsons
MATX
+$7.54M
2
PK icon
Park Hotels & Resorts
PK
+$6.53M
3
LNTH icon
Lantheus
LNTH
+$6.24M
4
PEGA icon
Pegasystems
PEGA
+$5.99M
5
CNM icon
Core & Main
CNM
+$5.29M

Sector Composition

Rank Sector Weight
1 Industrials 17.54%
2 Technology 15.26%
3 Financials 14.16%
4 Healthcare 13.52%
5 Consumer Discretionary 12.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ONL
1026
Orion Office REIT
ONL
$147M
$71K ﹤0.01%
+20,220
New +$90.7K
EHTH icon
1027
eHealth
EHTH
$42.9M
$63K ﹤0.01%
10,412
-5,276
-34% -$35K
DXLG icon
1028
Destination XL Group
DXLG
$34.8M
$61K ﹤0.01%
17,015
-25,860
-60% -$101K
FSP
1029
Franklin Street Properties
FSP
$46.1M
$61K ﹤0.01%
+26,992
New +$64.4K
ERAS icon
1030
Erasca
ERAS
$6.64B
$57K ﹤0.01%
27,640
-299,455
-92% -$599K
BW icon
1031
Babcock & Wilcox
BW
$1.64B
$55K ﹤0.01%
+48,580
New +$60.1K
IHRT icon
1032
iHeartMedia
IHRT
$547M
$53K ﹤0.01%
25,240
-7,690
-23% -$18.1K
ALDX icon
1033
Aldeyra Therapeutics
ALDX
$99.5M
$51K ﹤0.01%
+15,670
New +$51.5K
DOUG icon
1034
Douglas Elliman
DOUG
$155M
$51K ﹤0.01%
32,186
-401
-1% -$821
ABOS icon
1035
Acumen Pharmaceuticals
ABOS
$154M
$50K ﹤0.01%
+12,410
New +$46.8K
RMNI icon
1036
Rimini Street
RMNI
$397M
$49K ﹤0.01%
14,990
-16,820
-53% -$53.7K
DSGN icon
1037
Design Therapeutics
DSGN
$729M
$45K ﹤0.01%
11,080
-24,540
-69% -$65.5K
SGHC icon
1038
SGHC Ltd
SGHC
$7.37B
$43K ﹤0.01%
12,325
-6,148
-33% -$19.7K
SLQT icon
1039
SelectQuote
SLQT
$123M
$41K ﹤0.01%
20,410
-15,660
-43% -$23.4K
LONA
1040
LeonaBio Inc
LONA
$71.4M
$40K ﹤0.01%
+1,472
New +$46.7K
TRUE
1041
DELISTED
TrueCar
TRUE
$40K ﹤0.01%
11,692
-7,500
-39% -$26K
LTRX icon
1042
Lantronix
LTRX
$247M
$37K ﹤0.01%
10,330
-910
-8% -$4.46K
CMPX icon
1043
Compass Therapeutics
CMPX
$369M
$33K ﹤0.01%
+16,580
New +$28.7K
PRTS icon
1044
CarParts.com
PRTS
$36.4M
$33K ﹤0.01%
2,066
-1,218
-37% -$30.5K
NKTR icon
1045
Nektar Therapeutics
NKTR
$2.32B
$27K ﹤0.01%
1,962
-1,840
-48% -$19.3K
COOK icon
1046
Traeger
COOK
$188M
$26K ﹤0.01%
+209
New +$23.8K
PMVP icon
1047
PMV Pharmaceuticals
PMVP
$73.1M
$26K ﹤0.01%
15,130
-16,970
-53% -$31.7K
BHR
1048
Braemar Hotels & Resorts
BHR
$145M
$24K ﹤0.01%
11,890
-15,120
-56% -$33.4K
TDUP icon
1049
ThredUp
TDUP
$732M
$23K ﹤0.01%
11,440
-31,690
-73% -$64.6K
ACRS icon
1050
Aclaris Therapeutics
ACRS
$772M
$20K ﹤0.01%
+15,801
New +$18.8K

Similar funds

Algert Global's Q1 2024 Portfolio in Review

As of Q1 2024, Algert Global held 1,322 positions worth $2.55B, up 2.9% from $2.48B the previous quarter. Its ten largest holdings account for 5.3% of the portfolio.

Algert Global withdrew a net $81.9M in Q1 2024, closing 270 positions and reducing 433 holdings. Its most notable exit was Armstrong World Industries, an estimated $12.9M position sold in full.

By sector, the portfolio is most concentrated in Industrials at 18% of assets, up from 15% a quarter earlier, followed by Technology and Financials.

Against the trend, Algert Global opened a new position in Jones Lang LaSalle worth $5.67M.

  • Algert Global's largest Q1 2024 buy was Jones Lang LaSalle: 29,060 shares worth $5.67M.
  • Algert Global added most to Matsons in Q1 2024, an estimated $7.54M increase.
  • Algert Global's biggest Q1 2024 reduction was Rush Enterprises Class A, cutting an estimated $8.38M.
  • Algert Global fully exited Armstrong World Industries in Q1 2024, selling an estimated $12.9M.
  • Algert Global's ten largest holdings make up 5.3% of its $2.55B portfolio in Q1 2024.
  • Algert Global opened 211 new positions and closed 270 in Q1 2024.
  • Algert Global's portfolio value rose 2.9% quarter-over-quarter to $2.55B.

Based on Algert Global's 13F filing for Q1 2024, filed 15 May 2024.